CRL Charles River Laboratories (CRL) Q2 FY26 earnings call
Charles River Laboratories delivered a strong Q2 FY26, exceeding revenue and EPS expectations, driven by a significant rebound in DSA bookings and organic revenue growth. The company raised its full-year guidance, reflecting improving biopharmaceutical demand, particularly from small and mid-sized biotechs, and the benefits of portfolio refinement. Management is focused on strategic initiatives to modernize operations and deepen client relationships, positioning for sustained growth despite ongoing softness in academic and government spending.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CRL operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Backlog DSA | $1.92BAs previously mentioned, we are encouraged that the overall DSA demand environment is tracking to our expectation, resulting in a net book-to-bill of 1.04x and a slight sequential increase in backlog to $1.92 billion at the end of the first quarter.Source: earnings call transcript | $1.97BNet bookings increased significantly year-over-year and by 12.6% sequentially to $701 million in the second quarter resulting in an increase in the DSA backlog to $1.97 billion and a net book-to-bill of 1.9x.Source: earnings call transcript | +2.6% |
| Net bookings | $622MNet bookings totaled a solid $622 million, remaining above the $600 million threshold, driven by continued strength from our small and mid-sized biotech client base.Source: earnings call transcript | $701MNet bookings increased significantly year-over-year and by 12.6% sequentially to $701 million in the second quarter resulting in an increase in the DSA backlog to $1.97 billion and a net book-to-bill of 1.9x.Source: earnings call transcript | +12.7% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.